SMTI

Sanara Medtech Inc. (SMTI) - 10-K Summary for Fiscal Year Ended December 31, 2024

Business Context and Reporting Period

Company: Sanara Medtech Inc.
Reporting Period: Fiscal Year Ended December 31, 2024
Segments: The Company reorganized its reporting structure in Q2 2024 into two segments: Sanara Surgical (soft tissue repair and bone fusion products) and Tissue Health Plus (THP) (value-based wound care services).
Operations: Sanara Surgical generates the vast majority of revenue through products like CellerateRX Surgical and BIASURGE. The THP segment is in a pre-revenue build-out phase, preparing for a pilot program launch in Q2 2025.

Key Financial Metrics

Note: Segment Adjusted EBITDA is a non-GAAP measure used by management. The THP segment reported a net loss of $7.97 million in 2024 due to infrastructure build-out costs.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 33% year-over-year, driven by higher sales of soft tissue repair products (CellerateRX Surgical) and BIASURGE. A temporary surge in BIASURGE sales occurred in Q4 2024 due to supply chain shortages of IV fluids caused by Hurricane Helene.
• Profitability: While gross profit increased 37.4% due to higher sales volume and the elimination of certain royalties following the Applied Asset Purchase, the Net Loss widened significantly. This was primarily due to increased Selling, General, and Administrative (SG&A) expenses ($76.6M vs $57.0M) related to THP build-out, executive separation costs, and higher interest expense.
• Debt Structure: The Company refinanced its debt in April 2024, entering a $55.0 million CRG Term Loan facility. As of year-end, $30.5 million in principal was outstanding, replacing the previous Cadence Term Loan.

Guidance, Outlook, and Risks

Outlook and Strategy:

• THP Launch: The Company expects to launch its first value-based wound care pilot program in Q2 2025. Continued investment in THP is estimated at $7.5 million to $10.0 million for the first half of 2025.
• Debt Covenants: The CRG Term Loan requires the Company to maintain annual minimum revenues of $75.0 million in 2025, $85.0 million in 2026, and $95.0 million in 2027. The Company was in compliance with all covenants as of December 31, 2024.
• Recent Transactions: In January 2025, the Company acquired exclusive U.S. distribution rights to BMI's OsStic bone void filler and invested approximately €4.0 million in BMI equity.

Risks and Contingencies:

• Patent Exposure: The Company's lead product, CellerateRX Surgical, has no pending patent applications or unexpired patents, relying on trade secrets and regulatory barriers for protection.
• Liquidity: The Company relies on the CRG Term Loan and cash on hand to fund operations. Failure to meet revenue covenants could trigger an event of default.
• Regulatory: Operations are subject to FDA regulations; failure to maintain compliance or obtain clearances for new products could halt commercialization.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the Company's ability to meet the $75 million revenue minimum for the 2025 fiscal year required by the CRG Term Loan.
• THP Pilot Execution: Monitor the Q2 2025 launch of the Tissue Health Plus pilot program and its impact on future revenue streams.
• Patent Status: Review the competitive landscape for CellerateRX Surgical given the lack of patent protection and reliance on trade secrets.
• Interest Expense: Assess the impact of the 13.25% interest rate on the CRG Term Loan (including 5.25% paid-in-kind interest) on future cash flows.
• Related Party Transactions: Review ongoing royalty and service agreements with related parties, including Rochal Industries and The Catalyst Group.